Topical Antibiotic Treatment for Hidradenitis Suppurativa

Introduction to Topical Clindamycin

The American Academy of Dermatology recommends topical clindamycin 1% solution or gel applied twice daily for 12 weeks, combined with benzoyl peroxide, for the treatment of hidradenitis suppurativa, due to its efficacy in reducing superficial pustules, with a strength of evidence based on randomized controlled trials 1, 2

Topical clindamycin 1% is the only topical antibiotic that has been studied in randomized controlled trials for hidradenitis suppurativa, demonstrating reduction in pustules but no effect on inflammatory nodules and abscesses in patients with Hurley stage I or II disease, with a moderate strength of evidence 1
A 12-week placebo-controlled trial of 27 patients with Hurley stage I or II disease showed that topical clindamycin improved patient self-assessment, though its efficacy is limited to superficial lesions, with a moderate strength of evidence 1

The American Academy of Dermatology warns that topical clindamycin monotherapy significantly increases rates of Staphylococcus aureus resistance in patients with hidradenitis suppurativa, and recommends adding benzoyl peroxide to mitigate this risk, with a high strength of evidence 1

Antiseptic washes with chlorhexidine, benzoyl peroxide, or zinc pyrithione are recommended by the American Academy of Dermatology based on expert opinion for the treatment of hidradenitis suppurativa, though no specific data exist comparing agents, with a low strength of evidence 1, 2
Resorcinol 15% cream, a keratolytic and antiseptic, reduced pain and duration of abscesses when applied twice daily for flares and daily between flares in 12 women with Hurley stage I or II disease, but irritant dermatitis occurs frequently, limiting tolerability, with a moderate strength of evidence 1, 3
Intralesional triamcinolone 10 mg/mL demonstrated significant reductions in erythema, edema, suppuration, and lesion size, and improved pain visual analog scale scores, in a prospective case series, with a moderate strength of evidence 1, 3

The American Academy of Dermatology recommends topical clindamycin as first-line therapy for mild disease (Hurley stage I) with predominantly superficial pustules, but not for deep nodules or abscesses, with a high strength of evidence 1, 2, 3
For patients with moderate disease (Hurley stage II) or those with abscesses and inflammatory nodules, systemic antibiotics are more appropriate, with a high strength of evidence 1, 2

The standard treatment duration for topical clindamycin is 12 weeks, after which a treatment break should be considered to assess the need for ongoing therapy and limit antimicrobial resistance development, with a moderate strength of evidence 1, 2, 3
Response to treatment should be assessed using reduction in pustule count, patient-reported pain scores, and quality of life measures, with a moderate strength of evidence 1, 2